Researcher.Life Logo

BMC Infectious Diseases : Impact Factor & More

eISSN: 1471-2334pISSN: 1471-2334
JournalOpen Access

Key Metrics

CiteScore
4.8
Impact Factor
< 5
Scite Index
0.82 5-Year SI
SJR
Q2Infectious Diseases
SNIP
1.45
Recommended pre-submission checks
Powered by Paperpal by Editage

Topics Covered on BMC Infectious Diseases

BMC Infectious Diseases Journal Specifications

Indexed in the following public directories

  • Web of Science Web of Science
  • Scopus Scopus
  • DOAJ DOAJ
  • SJR SJR
Overview
Publisher BMC
Language English
Frequency Continuous publication
Article Processing ChargesEUR 2290 | USD 2690 | GBP 2090
Publication Time21
Editorial Review ProcessOpen peer review
General Details
LanguageEnglish
FrequencyContinuous publication
Publication Start Year2001
Publisher URLVisit website
Website URLVisit website
Publication Details
PlagiarismVisit website
Publication Time 21
Waiver PolicyVisit website
Editorial Review Detail
Editorial TeamVisit website
Review ProcessOpen peer review
Review UrlVisit website
Information for authors
Author instructionsVisit website
Copyright DetailsVisit website
Deposit PolicySherpa/Romeo
License typeCC BY, CC0
OA statementVisit website
View less

Planning to publish in BMC Infectious Diseases ?

Upload your Manuscript to get

  • Degree of match
  • Common matching concepts
  • Additional journal recommendations
Free Report

Recently Published Papers in BMC Infectious Diseases

The precision of behavioral intervention strategies remain one of the key strategies for HIV prevention among MSM in the era of pharmaceutical interventions: an ecological study.
  • 29 Oct 2025
  • BMC infectious diseases
Analysis of a rare case of vaginitis caused by Trichomonas vaginalis combined with fungal infection.
  • 29 Oct 2025
  • BMC infectious diseases
Seroprevalence of Immunoglobulin M and G antibodies to severe acute respiratory syndrome coronavirus 2 infection in Iwo, Nigeria.
  • 29 Oct 2025
  • BMC infectious diseases
Correlates of virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study.
  • 29 Oct 2025
  • BMC infectious diseases
Efficacy and safety of echinocandins combined with Trimethoprim-Sulfamethoxazole as first-line treatment for Pneumocystis pneumonia in HIV-infected and non-HIV-infected patients.
  • 29 Oct 2025
  • BMC infectious diseases
Emerging Neisseria meningitidis ST-1466 and ST-11026 as urogenital pathogens in China.
  • 29 Oct 2025
  • BMC infectious diseases
The precision of behavioral intervention strategies remain one of the key strategies for HIV prevention among MSM in the era of pharmaceutical interventions: an ecological study.
  • 29 Oct 2025
  • BMC infectious diseases
Analysis of a rare case of vaginitis caused by Trichomonas vaginalis combined with fungal infection.
  • 29 Oct 2025
  • BMC infectious diseases
Seroprevalence of Immunoglobulin M and G antibodies to severe acute respiratory syndrome coronavirus 2 infection in Iwo, Nigeria.
  • 29 Oct 2025
  • BMC infectious diseases
Correlates of virological non-suppression among children and adolescents aged 5-19 years on Dolutegravir-based regimens attending Gulu regional referral hospital, Northern Uganda: a mixed methods cross-sectional study.
  • 29 Oct 2025
  • BMC infectious diseases
Efficacy and safety of echinocandins combined with Trimethoprim-Sulfamethoxazole as first-line treatment for Pneumocystis pneumonia in HIV-infected and non-HIV-infected patients.
  • 29 Oct 2025
  • BMC infectious diseases
Emerging Neisseria meningitidis ST-1466 and ST-11026 as urogenital pathogens in China.
  • 29 Oct 2025
  • BMC infectious diseases

FAQs on BMC Infectious Diseases